Evidence map›Paper›PMID 36881618›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2023

Computational design of BclxL inhibitors that target transmembrane domain interactions.

Gerard Duart, Assaf Elazar, Jonathan Y Weinstein, Laura Gadea-Salom, Juan Ortiz-Mateu, Sarel J Fleishman, Ismael Mingarro, Luis Martinez-Gil

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. bioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Gerard DuartDepartment of Biochemistry and Molecular Biology, Institut de Biotecnologia i Biomedicina, Universitat de València, Burjassot 46100, Spain.ORCID 0000-0002-9012-3164
Assaf ElazarDepartment of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 76100, Israel.
Jonathan Y WeinsteinDepartment of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 76100, Israel.ORCID 0000-0001-7581-965X
Laura Gadea-SalomDepartment of Biochemistry and Molecular Biology, Institut de Biotecnologia i Biomedicina, Universitat de València, Burjassot 46100, Spain.ORCID 0000-0001-8945-185X
Juan Ortiz-MateuDepartment of Biochemistry and Molecular Biology, Institut de Biotecnologia i Biomedicina, Universitat de València, Burjassot 46100, Spain.ORCID 0000-0003-3597-4481
Sarel J FleishmanDepartment of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 76100, Israel.ORCID 0000-0003-3177-7560
Ismael MingarroDepartment of Biochemistry and Molecular Biology, Institut de Biotecnologia i Biomedicina, Universitat de València, Burjassot 46100, Spain.ORCID 0000-0002-1910-1229
Luis Martinez-GilDepartment of Biochemistry and Molecular Biology, Institut de Biotecnologia i Biomedicina, Universitat de València, Burjassot 46100, Spain.ORCID 0000-0002-9076-7760
Universitat de València · ESWeizmann Institute of Science · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several methods have been developed to explore interactions among water-soluble proteins or regions of proteins. However, techniques to target transmembrane domains (TMDs) have not been examined thoroughly despite their importance. Here, we developed a computational approach to design sequences that specifically modulate protein-protein interactions in the membrane. To illustrate this method, we demonstrated that BclxL can interact with other members of the B cell lymphoma 2 (Bcl2) family through the TMD and that these interactions are required for BclxL control of cell death. Next, we designed sequences that specifically recognize and sequester the TMD of BclxL. Hence, we were able to prevent BclxL intramembrane interactions and cancel its antiapoptotic effect. These results advance our understanding of protein-protein interactions in membranes and provide a means to modulate them. Moreover, the success of our approach may trigger the development of a generation of inhibitors targeting interactions between TMDs.

Indexed as

WaterCell DeathProtein DomainsWaterBclxLde novo designmembrane-active proteinsmembrane proteinprotein design

Identifiers

PMID36881618
PMCPMC10089226
OpenAlexW4323347641

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.